Cellectar Biosciences, a Madison company working on cancer-fighting compounds, reported a net loss of $5.5 million, or $7.03 a share for the 2015 fiscal year, down from a net loss of $8.1 million, or $17.53 a share, for 2014. Read the full Wisconsin State Journal story here.
- DataChat Closes $4 Million Seed Round to Accelerate the Democratization of Data AnalyticsOctober 20, 2020
- EHRN: Trends in Overall and Non-COVID-19 Hospital AdmissionsOctober 20, 2020
- Can Wisconsin lead bio-industrial surge? Find out at 2020 Early Stage SymposiumOctober 20, 2020
- Returning military vets, students may register at discount to attend November Early Stage eventOctober 19, 2020
- InsideWis: Anticipated COVID-19 flattening of early stage investing hasn’t occurredOctober 15, 2020